BTT-1023 in Rheumatoid Arthritis

Biotie Therapies

Status and phase: Completed; Phase 1

Conditions: Rheumatoid Arthritis

Treatments: Drug: Placebo; Drug: BTT-1023

Study type: Interventional

Funder types: Industry

Identifiers

NCT00851240

BTT12-CD015

Details and patient eligibility

About

Patients with adult-onset rheumatoid arthritis will be enrolled. They will be dosed with repeated intravenous doses of BTT-1023 or placebo. During the trial, the safety of the treatments and the pharmacokinetics of BTT-1023 will be assessed. The patient allocation to treatment groups will occur at random, and the actual treatment will not be revealed to the investigator or to the patient during the trial.

Enrollment: 24 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• adult-onset rheumatoid arthritis

Exclusion criteria

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

24 participants in 2 patient groups, including a placebo group

BTT1023

Experimental group

Treatment:

Drug: BTT-1023

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo